Afshin Dowlati, MD
Schedule an Appointment
Biography
- Lucile and Robert H Gries Endowed Director, Center for Cancer Drug Development, University Hospitals
- Director, Thoracic Oncology Program, UH Seidman Cancer Center
- Director, Thoracic Oncology, UH Cleveland Medical Center
- Director, Phase I Drug Development Program, UH Cleveland Medical Center
- Professor, CWRU School of Medicine
Expertise
- Experimental Therapeutics
- Hematology/Oncology
- Lung Cancer
- Phase I Clinical Trials
- Thoracic Cancer
Languages Spoken
English, French, Farsi
Office Locations
Patient Experience Reviews
4.9 out of 5
80 Ratings
Patient Comments (24)
Reviewed On 10/1/2021
I cannot speak too highly of the overall level of care I have received from Dr. Dowlati and my entire team at ***. Regardless of the eventual outcome of my cancer I will always be grateful to them for everything they have done for me and for the caring, compassionate and supportive attitude they have brought to my treatment
Reviewed On 10/1/2021
Excellent visit
Reviewed On 9/1/2021
Excellent experience
Reviewed On 9/1/2021
I would almost certainly be dead if not for the skill and knowledge of Dr Dowlati. Therefore I can't say enough positive about him. The fact that he is personable and compassionate enhances what a remarkable doctor. Further, I have yet to encounter a single health care professional at the seidman cancer center that I can make any comment that is anything but positive. In the worst of situations I have fallen into the best of circumstances. Thank You
Reviewed On 8/1/2021
excellent care
Reviewed On 8/1/2021
excellent care & always have been!
Reviewed On 6/1/2021
The experience was excellent .
Reviewed On 6/1/2021
Wonderful caring individual. Called a conference with other specialists to see what everyone thought would be best long term care for my condition. Confident in his treatment decisions.
Reviewed On 5/1/2021
one of the nicest most caring doctors that I have ever had.
Reviewed On 5/1/2021
Consistent with previous positive experience.
Reviewed On 5/1/2021
good Answered all my questions
Reviewed On 4/1/2021
I cannot speak too highly of Dr. Dowlati and his team, or everyone I have so far come into contact with at UH Seidman Center on the main campus.
Reviewed On 4/1/2021
My oncologist is great. He is always concerned about my well being
Reviewed On 3/1/2021
Dr. Dowlati is a great physician and I appreciate his hard work.
Reviewed On 3/1/2021
Good
Reviewed On 3/1/2021
A very good experience
Reviewed On 2/1/2021
excellent
Reviewed On 2/1/2021
Dr Dowlati is very caring and patient oriented physician. ***
Reviewed On 1/1/2021
excellent staff, excellent doctor, professional, compassionate & helpful.
Reviewed On 1/1/2021
Dr. Diwali is the best. His staff is excellent!. The staff and nurses, *** in the infusion department are excellent and very compassionate. *** and l love them!!!
Reviewed On 1/1/2021
I am very happy with the doctor ***
Reviewed On 12/1/2020
good
Reviewed On 12/1/2020
I have been very pleased with Dr. Dowlati's care. He has always been supportive of me during my illness and has offered me choice in my treatment.
Reviewed On 12/1/2020
My Dr is amazing and I am very grateful. ***
Board Certifications
- Medical Oncology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Education
Residency | Internal Medicine
Internal Medicine - University Hospitals Of Cleveland (1998 - 2000)
Fellowship | Hematology/Oncology
Hematology/Oncology - University Hospitals Of Cleveland (1996 - 1998)
Internship | Internal Medicine
Internal Medicine - Universite De Liege Faculte De Medecine (1992 - 1996)
Medical Education
Universite De Liege Faculte De Medecine (1992)
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Afshin Dowlati did not disclose any Outside Relationships with Industry.